Reference
Cowan JF, et al. Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States. Clinical Infectious Diseases : 10 Dec 2016. Available from: URL: http://doi.org/10.1093/cid/ciw803
Rights and permissions
About this article
Cite this article
Xpert testing for pulmonary TB cost effective in US inpatients. PharmacoEcon Outcomes News 769, 32 (2017). https://doi.org/10.1007/s40274-017-3668-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3668-6